SYRE
Spyre Therapeutics, Inc.+$3.76 (3.94%) At close $99.27 · Today
☾After Hours −$6.27 (6.32%) Nov 3, 7:59 PM ET
About SYRE
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Cylvex Score
Some risk factors elevated
Multi-factor score. Not a buy/sell signal.
Score history
CalibratingScore history is calibrating — it appears once enough daily scores are recorded.
What goes into the score
6 axes · equal weightThe Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.